A new study led by clinician-scientists from the National Cancer Centre Singapore (NCCS), with collaborators from research institutions worldwide, has found that angiosarcomas have unique genomic and ...

Breast sarcomas and angiosarcomas represent a group of rare, heterogeneous tumours that pose significant challenges in diagnosis and management. These malignancies can occur as primary lesions or ...

Angiosarcomas are aggressive soft-tissue sarcomas that are associated with high rates of local and distant recurrence and poor outcomes. [1,2] Close review of patient series and tumor characteristics ...

Pazopanib produced responses and acceptable safety in paclitaxel-pretreated angiosarcoma; read more about outcomes and ...

Angiosarcomas have unique genomic and immune profiles. They can be classified into three different subtypes. So, patients can be treated using a personalized-medicine approach. Angiosarcomas, a type ...

Cutaneous angiosarcoma is a rare, highly aggressive skin tumor found primarily on the scalps of older White people, but based on new research from the University of North Carolina School of Medicine ...

A common heart drug may stop the progression of angiosarcoma, a cancer of the inner lining of blood vessels, according to a study. Angiosarcomas are highly lethal tumors that can occur in any part of ...

Another factual information on the “Global Angiosarcomas Treatment Market” has as of late added by CMI to its storehouse. This global research report offers an inside and out examination of various ...

The fashion world was in shock following the passing of fashion designer Virgil Abloh at the age of 41, after a 2-year private battle with cardiac angiosarcoma, a rare cancer. Abloh first came to ...

Virgil Abloh — founder of streetwear brand Off-White, artistic director of men’s Louis Vuitton line and one of Time Magazine’s 100 most influential people — recently died from a cardiac angiosarcoma.

Could Targeted Therapies Extend Survival? Medscape: How do you approach patients with recurrent or metastatic disease? What are the key areas of focus for these patients? Dr. D'Angelo: We know from ...